Addex Therapeutics Awarded $1 MM Grant from The Michael J. Fox Foundation for Parkinson's Research

Addex Partners with Viva Biotech to Advance Allosteric Modulators Targeting Adenosine 2A Receptor

Addex Therapeutics Reports 2012 Financial Results

Addex to Focus Resources on Clinical Pipeline

Addex Dipraglurant Reduces Motor Abnormalities in a Preclinical Model Relevant for Several Rare types of Dystonia

Addex Announces Issuance of a Broad US Composition of Matter Patent for ADX71441

Addex Announces Positive Data with ADX71441 in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease

Addex Scientists Discover and Characterize the First Potent and Selective Small Molecule Negative Allosteric Modulator Targeting mGlu7 receptor

Addex’ Dipraglurant Named as one of the “Top 10 Neuroscience Projects to Watch” by Windhover and Virginia Herndon

Addex Reports Top-line Data from a Successful Phase 2a Clinical Study with ADX71149 in Schizophrenia Patients